SEC Form 4	
------------	--

П

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL										
OMB Number: 3235-0287										
Estimated average burden										
hours per response:	0.5									

1. Name and Address of Reporting Person [*] Aviezer David			2. Issuer Name and Ticker or Trading Symbol <u>Protalix BioTherapeutics, Inc.</u> [PLX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner
(Last) (First) (Middle)		(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	X Officer (give title Other (specify below)
(Last) C/O PROTAL	()	APEUTICS, INC.	05/04/2009	President & CEO
2 SNUNIT STREET, SCIENCE PARK, POB 455				
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)
CARMIEL	L3	20100		X Form filed by One Reporting Person
(City)	(State)	(Zip)	-	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Table 1 - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		
Common Stock	05/04/2009		S		33,400 ⁽¹⁾	D	\$ <mark>3.0</mark> 1	0(2)	Ι	By Trust ⁽³⁾		
Common Stock	05/05/2009		S		21,600 ⁽¹⁾	D	\$3.07	0 ⁽²⁾	I	By Trust ⁽³⁾		
Common Stock	05/06/2009		S		20,000(1)	D	\$3.01	0(2)	I	By Trust ⁽³⁾		
Common Stock	05/06/2009		м		78,061	A	\$0.12	0(2)	I	By Trust ⁽³⁾		
Common Stock	05/06/2009		F		3,061	D	\$3.06	0(2)	Ι	By Trust ⁽³⁾		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (Right to Buy)	\$0.12	05/06/2009		М			78,061	(4)	12/08/2013	Common Stock	78,061	\$0	677,328 ⁽⁵⁾	D	

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

2. The reporting person acquired 75,000 shares of common stock upon the exercise of outstanding options, all of which shares were sold by the reporting person.

3. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee upon the exercise of stock options must be registered in the name of a trustee.

4. All of the options listed in Table II have vested.

5. Does not include options to purchase 977,296 shares of common stock at an exercise price equal to \$0.972 per share that expire on 9/10/2016, options to purchase 600,000 shares of common stock at an exercise price equal to \$5.00 per share that expire on February 7, 2018, and options to purchase 100,000 shares of common stock at an exercise price equal to \$2.65 that expire on February 25, 2019.

<u>/s/ Yossi Maimon</u> ** Signature of Reporting Person 05/06/2009 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.